All eyes are on Washington today as healthcare reform makes its way through Congress. Before a joint session of Congress last night, President Obama delivered a speech that he hopes will be the final push needed to drive a bill through the House and Senate and to his desk. He outlined particulars of what he hopes to see in a healthcare bill, and declared that “the character of our country” demands swift action to solve the problem. If you missed it, you can read the address HERE.


Obama

BIO is taking the lead on making sure that any healthcare reform effort protects medical innovation and progress through biotechnology. Responding to Obama’s speech, BIO President and CEO Jim Greenwood issued this statement:

“BIO shares President Obama’s goal of ensuring that all Americans have access to affordable, sustainable, high quality health care. Biotechnology plays an essential role in achieving this goal. Biotechnology expands the boundaries of science by discovering, developing, and delivering innovative and needed medical products to patients. Medical innovation in health care that leads to medical advancements and breakthroughs, including health care solutions such as new therapies and diagnostics, has always been and will continue to be central to realizing our health care goals.”

BIO’s statement specifically addressed the biosimilars issue, emphasizing the bipartisan support for a fair approval pathway in both the House and Senate:

“Congress can help expand access to biologic medicines, and expand hope, by establishing a pathway for the regulatory approval of biosimilars, medicines that are similar to but not the same as pioneering biologic medicines. Both the Senate Committee on Health, Education, Labor and Pensions (HELP) and the House Energy and Commerce Committees included biosimilars provisions in their health care reform bills. These provisions received strong bipartisan support in each committee.”

Yesterday, Greenwood and BIO’s Chairman Dr. Stephen Sherwin also held a media briefing to outline where BIO stands on key federal policy issues. Among other topics, they addressed healthcare reform, possible energy legislation, and the current business climate for biotech firms. Kevin Noonan at PatentDocs has a very detailed summary of the briefing.

Read the full text of Jim Greenwood’s statement on Obama’s healthcare address after the jump.

***

Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement in response to President Obama`s address on health care reform delivered tonight before a joint session of the U.S. Congress:

“BIO shares President Obama’s goal of ensuring that all Americans have access to affordable, sustainable, high quality health care. Biotechnology plays an essential role in achieving this goal. Biotechnology expands the boundaries of science by discovering, developing, and delivering innovative and needed medical products to patients. Medical innovation in health care that leads to medical advancements and breakthroughs, including health care solutions such as new therapies and diagnostics, has always been and will continue to be central to realizing our health care goals.

“Further, market-based reforms provide the best opportunity to achieve the goal of universal access while providing high quality care and incentives for the discovery and development of innovative improvements throughout the health care delivery system.

“Through biologic medicines, therapies and diagnostic tools, biotechnology also provides the best hope for reducing the incidence of chronic disease. In this way, biotechnology can provide measurable benefits in increased productivity, while at the same time saving the scarce health care dollars spent on treating such diseases. Biotechnology also can provide the immeasurable benefits of saving, extending and improving the quality of life for patients living with debilitating diseases such as cancer, Parkinson`s, diabetes and multiple sclerosis.

“Congress can help expand access to biologic medicines, and expand hope, by establishing a pathway for the regulatory approval of biosimilars, medicines that are similar to but not the same as pioneering biologic medicines. Both the Senate Committee on Health, Education, Labor and Pensions (HELP) and the House Energy and Commerce Committees included biosimilars provisions in their health care reform bills. These provisions received strong bipartisan support in each committee.

“The language adopted by the committees strikes the necessary balance among expanding access and competition, ensuring patient safety and promoting continued biomedical innovation that will lead to new and improved medicines and treatments. This language is a `win-win` for the patients of today and the patients of tomorrow.

“We urge the Congress to include this biosimilars language as they continue efforts to reform our nation`s health care system. We look forward to continuing our participation in the process of health care reform with the goal of increasing access and reducing costs while promoting the continued development of new therapies and cures.”